New technique enables faster genetic diagnosis for hereditary diseases

By means of this technique, genetic tests that take a long time today – such as screening for hereditary forms of breast cancer – can be carried out much more rapidly. This finding creates new perspectives for tests that are currently expensive and difficult to perform.

Genetic screening today
Genetic screening is currently performed when, for example, several persons in a family contract the same disease. A member of the family may wonder whether it is in fact an hereditary disease, and, if so, whether he or she is a carrier and runs the risk of getting the disease or of transmitting it to his or her children. Following genetic advice, screening can be performed: whereby scientists investigate whether there is indeed a defect in the DNA of the patients in the family (provided they cooperate in the testing) or of the family member who is inquiring. On the basis of this screening, medical practitioners can provide advice regarding prevention or regarding prenatal diagnosis when the person desires to have children.

If the gene that can cause the disease is very large, or if there are several genes that can possibly lead to the disease, diagnostic centers must conduct a lot of labor-intensive studies. This results in long waiting times, with the consequences that the person inquiring remains in a state of uncertainty for a longer time, that any preventive treatment is delayed, that a desire to have children is postponed, or that children are born with a defective gene.

A new technology
Now, VIB researchers Dirk Goossens and his colleagues in Jurgen Del-Favero’s research group have developed a new method, with which several pieces of DNA can be examined simultaneously, instead of one after the other. They have succeeded in joining together two powerful existing techniques – multiplex PCR and massive parallel sequencing – making it possible to screen all of a person’s relevant hereditary matter at one time. Use of this parallel technology offers an affordable solution for molecular diagnostics of a large number of (sometimes commonly occurring) disorders.
A much quicker diagnosis
With this new technology, the molecular diagnosis of genetic diseases – such as breast cancer, cystic fibrosis, and hereditary deafness – will be carried out much faster and more cost-effectively. It takes 3 to 6 months to receive a result with the techniques that are currently in use. By comparison, the new method produces a result within only a few weeks. Moreover, not only are these tests run much more quickly, they are also very sensitive and provide a more detailed result.

Media Contact

Sooike Stoops alfa

More Information:

http://www.vib.de

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

Bringing bio-inspired robots to life

Nebraska researcher Eric Markvicka gets NSF CAREER Award to pursue manufacture of novel materials for soft robotics and stretchable electronics. Engineers are increasingly eager to develop robots that mimic the…

Bella moths use poison to attract mates

Scientists are closer to finding out how. Pyrrolizidine alkaloids are as bitter and toxic as they are hard to pronounce. They’re produced by several different types of plants and are…

AI tool creates ‘synthetic’ images of cells

…for enhanced microscopy analysis. Observing individual cells through microscopes can reveal a range of important cell biological phenomena that frequently play a role in human diseases, but the process of…

Partners & Sponsors